In addition, the vast majority of HR+/HER2+ breast cancer patients have received trastuzumab, and over half have been treated with anthracyclines; both of these therapies have some degree of cardiotoxicity, which may further be enhanced by OFS drugs. This evidence concerns the gene ERBB2 and breast cancer.